Penumbra is facing growth impacts due to uncertainties regarding FDA review timelines and revenue decline in China.

The entities involved

• Penumbra →

  medical device company in Alameda, California

  • A tariff plan caused market tanking on August 22, 2025, impacting publicly traded companies including Golden Entertainment and AbbVie.Sun 04:31
• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• China →

  cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China

  • The European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Mon 17:49
  • The Middle Corridor, linking Central Asia and Europe, is gaining significance in regional trade and energy routes.Mon 17:06

Related events

• FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.Jun 8
• Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.Sep 10
• The US administration rejected a proposed FDA-style central AI regulator while acknowledging the need to compete with China in the AI race.Jul 5
• Morgan Stanley highlighted guidance regarding Nvidia's sales, noting that market uncertainty surrounding China impacts the company's outlook.Jun 7
• FDA clearance enables market entry into the U.S. for an unnamed company, which is also navigating the long-term regulatory process in Japan.Aug 12